{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:58:25Z","timestamp":1790848705010,"version":"4.1.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Multi-Investigator Research Award PILOT PROJECTS","award":["RP240439"],"award-info":[{"award-number":["RP240439"]}]},{"DOI":"10.13039\/100007144","name":"University of Houston","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007144","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Conventional antibody\u2013drug conjugates (ADCs) are typically limited to drug-to-antibody ratios (DARs) of \u22648 because of restricted conjugation sites and unfavorable physicochemical properties at higher DARs, including increased hydrophobicity, aggregation, and rapid systemic clearance. Consequently, most clinically approved ADCs rely on highly potent cytotoxic payloads (e.g. IC50\u00a0&amp;lt;\u00a01\u00a0nM), which can result in significant off-target toxicities. This mini-review summarizes recent advances in next-generation ultrahigh-DAR antibody therapeutics, with a particular focus on two emerging platforms: antibody polymer conjugates (APCs) and antibody\u2013nanoparticle conjugates (ANCs). We discuss their design principles, structural features, and strategies for achieving high payload loading while preserving antigen recognition and favorable pharmacokinetic properties. Recent advances in APCs and ANCs demonstrate that polymer and nanomaterial engineering can overcome the conventional DAR limitations of ADCs, enabling substantially greater payload loading per targeting antibody without compromising targeting performance. These ultrahigh-DAR platforms also expand the range of deliverable payloads, facilitating the development of therapeutics with diverse mechanisms of action beyond traditional ultrapotent cytotoxic agents. Ultrahigh-DAR antibody therapeutics represent a promising next generation of targeted drug delivery systems. By integrating advances in polymer and nanomaterial engineering, APCs and ANCs have the potential to broaden the therapeutic landscape of antibody-based medicines and enable safer, more effective targeted therapies across a wide range of diseases.<\/jats:p>","DOI":"10.1093\/abt\/tbag042","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:24:11Z","timestamp":1786706651000},"page":"566-575","source":"Crossref","is-referenced-by-count":0,"title":["Ultrahigh-DAR antibody\u2013drug conjugates: advancing the next generation of targeted therapy"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1031-7733","authenticated-orcid":false,"given":"Haosheng","family":"Feng","sequence":"first","affiliation":[{"name":"Center for Nuclear Receptors and Cell Signaling, University of Houston , Houston, TX 77204 ,","place":["United States"]},{"name":"Department of Biology and Biochemistry, University of Houston , Houston, TX 77204 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1736-9392","authenticated-orcid":false,"given":"Bin","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Nuclear Receptors and Cell Signaling, University of Houston , Houston, TX 77204 ,","place":["United States"]},{"name":"Department of Biology and Biochemistry, University of Houston , Houston, TX 77204 ,","place":["United States"]},{"name":"Department of Chemistry, University of Houston , Houston, TX 77204 ,","place":["United States"]},{"name":"Department of Biomedical Engineering, University of Houston , Houston, TX 77204 ,","place":["United States"]},{"name":"Program of Materials Science and Engineering, University of Houston , Houston, TX 77204 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026100105270858600_ref1","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.3390\/molecules28062605","article-title":"Antibody\u2013biopolymer conjugates in oncology: a review","volume":"28","author":"Chavda","year":"2023","journal-title":"Molecules"},{"key":"2026100105270858600_ref2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3390\/molecules28030917","article-title":"Site-specific antibody conjugation with payloads beyond cytotoxins","volume":"28","author":"Zhou","year":"2023","journal-title":"Molecules"},{"key":"2026100105270858600_ref3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"2026100105270858600_ref4","doi-asserted-by":"publisher","first-page":"9303","DOI":"10.1039\/D0SC01795G","article-title":"A poly-ADP-ribose polymer-based antibody-drug conjugate","volume":"11","author":"Shi","year":"2020","journal-title":"Chem Sci"},{"key":"2026100105270858600_ref5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody\u2013drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull"},{"key":"2026100105270858600_ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-025-02772-z","article-title":"Antibody\u2013bottlebrush prodrug conjugates for targeted cancer therapy","volume":"44","author":"Liu","journal-title":"Nat Biotechnol"},{"key":"2026100105270858600_ref7","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2026100105270858600_ref8","doi-asserted-by":"publisher","first-page":"123464","DOI":"10.1016\/j.biomaterials.2025.123464","article-title":"CD38-targeted antibody-polymer drug conjugates for enhanced treatment of multiple myeloma","volume":"324","author":"Li","year":"2026","journal-title":"Biomaterials"},{"key":"2026100105270858600_ref9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1039\/D3PM00075C","article-title":"Polymer\u2013drug conjugates as nano-sized multi-targeting systems for the treatment of Alzheimer\u2019s disease","volume":"1","author":"Mahadik","year":"2024","journal-title":"RSC Pharm"},{"key":"2026100105270858600_ref10","doi-asserted-by":"publisher","first-page":"113682","DOI":"10.1016\/j.jconrel.2025.113682","article-title":"PD-L1 targeted antibody-polymer-epirubicin conjugate prolongs survival in a preclinical murine model of advanced ovarian cancer","volume":"382","author":"Li","year":"2025","journal-title":"J Control Release"},{"key":"2026100105270858600_ref11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1158\/1535-7163.MCT-20-0166","article-title":"Dolaflexin: a novel antibody\u2013drug conjugate platform featuring high drug loading and a controlled bystander effect","volume":"20","author":"Yurkovetskiy","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2026100105270858600_ref12","doi-asserted-by":"publisher","first-page":"122285","DOI":"10.1016\/j.biomaterials.2023.122285","article-title":"Preparation of an ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy","volume":"301","author":"Zhang","year":"2023","journal-title":"Biomaterials"},{"key":"2026100105270858600_ref13","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3762\/bjnano.14.75","article-title":"Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics","volume":"14","author":"Kumari","year":"2023","journal-title":"Beilstein J Nanotechnol"},{"key":"2026100105270858600_ref14","doi-asserted-by":"publisher","first-page":"e2409635","DOI":"10.1002\/smll.202409635","article-title":"Antibody-nanoparticle conjugates in therapy: combining the best of two worlds","volume":"21","author":"Adhikari","year":"2025","journal-title":"Small"},{"key":"2026100105270858600_ref15","doi-asserted-by":"publisher","first-page":"113876","DOI":"10.1016\/j.jconrel.2025.113876","article-title":"Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas","volume":"384","author":"Lidick\u00fd","year":"2025","journal-title":"J Control Release"},{"key":"2026100105270858600_ref16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jconrel.2020.06.040","article-title":"HPMA copolymer-antibody constructs in neoplastic treatment: an overview of therapeutics, targeted diagnostics, and drug-free systems","volume":"325","author":"Rand\u00e1rov\u00e1","year":"2020","journal-title":"J Control Release"},{"key":"2026100105270858600_ref17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jconrel.2009.07.011","article-title":"HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity","volume":"140","author":"Etrych","year":"2009","journal-title":"J Control Release"},{"key":"2026100105270858600_ref18","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/1535-7163.MCT-20-0183","volume":"20","author":"Bodyak","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2026100105270858600_ref19","doi-asserted-by":"publisher","first-page":"114570","DOI":"10.1016\/j.addr.2022.114570","article-title":"Recombinant protein polymer-antibody conjugates for applications in nanotechnology and biomedicine","volume":"191","author":"Goncalves","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"2026100105270858600_ref20","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1039\/D1SC05243H","article-title":"A homogeneous high-DAR antibody\u2013drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides","volume":"13","author":"Zacharias","year":"2022","journal-title":"Chem Sci"},{"key":"2026100105270858600_ref21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1021\/acs.bioconjchem.1c00098","article-title":"Molecular dynamics-guided design of a functional protein\u2013ATRP conjugate that eliminates protein\u2013protein interactions","volume":"32","author":"Kaupbayeva","year":"2021","journal-title":"Bioconjug Chem"},{"key":"2026100105270858600_ref22","doi-asserted-by":"publisher","first-page":"13575","DOI":"10.1021\/ja104493d","article-title":"Genetically encoded initiator for polymer growth from proteins","volume":"132","author":"Peeler","year":"2010","journal-title":"J Am Chem Soc"},{"key":"2026100105270858600_ref23","volume-title":"Myris Therapeutics is Developing Ultra-High DAR ADCs to Enable Novel Precision Medicine Treatments for Cancer","author":"Myris Therapeutics, Inc","year":"2025"},{"key":"2026100105270858600_ref24","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1007\/s13346-025-01947-0","article-title":"Antibody-conjugated polymer nanoparticles for brain cancer","volume":"15","author":"Tai","year":"2025","journal-title":"Drug Deliv Transl Res"},{"key":"2026100105270858600_ref25","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1021\/acs.biomac.2c01269","article-title":"Targeted drug delivery using a plug-to-direct antibody\u2013nanogel conjugate","volume":"24","author":"Huynh","year":"2023","journal-title":"Biomacromolecules"},{"key":"2026100105270858600_ref26","first-page":"2143","article-title":"Development of high-drug-loading nanoparticles","volume":"85","author":"Liu","year":"2020","journal-title":"Chem Plus Chem"},{"key":"2026100105270858600_ref27","doi-asserted-by":"publisher","first-page":"12813","DOI":"10.1002\/anie.202103106","article-title":"Protein\u2013antibody conjugates (PACs): a plug-and-play strategy for covalent conjugation and targeted intracellular delivery of pristine proteins","volume":"60","author":"Liu","year":"2021","journal-title":"Angew Chem Int Ed"},{"key":"2026100105270858600_ref28","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1021\/acs.chemrev.5b00589","article-title":"Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies","volume":"116","author":"Ulbrich","year":"2016","journal-title":"Chem Rev"},{"key":"2026100105270858600_ref29","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S1470-2045(12)70476-X","article-title":"Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study","volume":"13","author":"Mamot","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026100105270858600_ref30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ejps.2009.07.006","article-title":"Nanomedicines for active targeting: Physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells","volume":"38","author":"Cirstoiu-Hapca","year":"2009","journal-title":"Eur J Pharm Sci"},{"key":"2026100105270858600_ref31","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.msec.2018.06.059","article-title":"Comparison of adsorption and conjugation of Herceptin on poly(lactic-co-glycolic acid) nanoparticles\u2014effect on cell internalization in breast cancer cells","volume":"92","author":"Choi","year":"2018","journal-title":"Mater Sci Eng C"},{"key":"2026100105270858600_ref32","doi-asserted-by":"publisher","first-page":"PO3-18\u201312","DOI":"10.1158\/1538-7445.SABCS23-PO3-18-12","article-title":"Abstract PO3-18-12: results from a first-in-human study of DAN-222, a novel high-capacity drug conjugate in metastatic breast cancer as monotherapy and in combination with a PARPi [NCT05261269]","volume":"84","author":"Hurvitz","year":"2024","journal-title":"Cancer Res"},{"key":"2026100105270858600_ref33","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS21-P2-13-09","article-title":"Abstract P 2-13-09: an investigational next generation ADC (DAN-311) is highly effective in HER2-low breast cancer models","volume":"82","author":"Wright","year":"2022","journal-title":"Cancer Res"},{"key":"2026100105270858600_ref34","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1158\/1538-7445.AM2025-1798","article-title":"Abstract 1798: K-679: a novel, ultra-high-DAR antibody drug-loaded unimicelle conjugate (ADUC) enabling more effective treatment in EGFR-expressing solid tumors compared to general ADCs","volume":"85","author":"Yoshida","year":"2025","journal-title":"Cancer Res"},{"key":"2026100105270858600_ref35","doi-asserted-by":"crossref","first-page":"2007787","DOI":"10.1002\/adma.202007787","article-title":"Daratumumab immunopolymersome-enabled safe and CD38-targeted chemotherapy and depletion of multiple myeloma","volume":"33","author":"Yu","year":"2021","journal-title":"Adv Mater"},{"key":"2026100105270858600_ref36","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3109\/10717544.2013.876460","article-title":"Treatment of glioma by cisplatin-loaded nanogels conjugated with monoclonal antibodies against Cx43 and BSAT1","volume":"22","author":"Baklaushev","year":"2015","journal-title":"Drug Deliv"},{"key":"2026100105270858600_ref37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jconrel.2021.11.014","article-title":"An intelligent cell-selective polymersome-DM1 nanotoxin toward triple negative breast cancer","volume":"340","author":"Zhang","year":"2021","journal-title":"J Control Release"},{"key":"2026100105270858600_ref38","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1158\/1078-0432.CCR-23-3196","article-title":"A phase I trial of nab-paclitaxel\/bevacizumab (AB160) nano-immunoconjugate therapy for gynecologic malignancies","volume":"30","author":"Kalogera","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026100105270858600_ref39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1021\/acs.molpharmaceut.3c00735","article-title":"Unleashing the potential: designing antibody-targeted lipid nanoparticles for industrial applications with CMC considerations and clinical outlook","volume":"21","author":"Wang","year":"2024","journal-title":"Mol Pharm"},{"key":"2026100105270858600_ref40","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-025-01330-w","article-title":"Preparation of targeted lipid nanoparticles for precision nucleic acid delivery","author":"Geisler","year":"2026","journal-title":"Nat Protoc"},{"key":"2026100105270858600_ref41","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41565-025-01954-9","article-title":"A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles","volume":"20","author":"Chen","year":"2025","journal-title":"Nat Nanotechnol"},{"key":"2026100105270858600_ref42","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"2026100105270858600_ref43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"2026100105270858600_ref44","doi-asserted-by":"publisher","first-page":"e2402874","DOI":"10.1002\/smll.202402874","article-title":"Antibody-directing antibody conjugates (ADACs) enabled by orthogonal click chemistry for targeted intracellular delivery","volume":"20","author":"Gong","year":"2024","journal-title":"Small"},{"key":"2026100105270858600_ref45","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1021\/ma0707638","article-title":"PEG brush peptide nanospheres with stealth properties and chemical functionality","volume":"40","author":"Waku","year":"2007","journal-title":"Macromolecules"},{"key":"2026100105270858600_ref46","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s12672-024-01509-9","article-title":"Polymer-drug conjugates: revolutionizing nanotheranostic agents for diagnosis and therapy","volume":"15","author":"Parashar","year":"2024","journal-title":"Discov Onc"},{"key":"2026100105270858600_ref47","doi-asserted-by":"publisher","first-page":"105219","DOI":"10.1016\/j.critrevonc.2026.105219","article-title":"Antibody-nanoparticle conjugates for precision targeting of immunosuppressive tumor microenvironment","volume":"221","author":"Fattahi","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026100105270858600_ref48","doi-asserted-by":"publisher","first-page":"100558","DOI":"10.1016\/j.nxnano.2026.100558","article-title":"Next-generation antibody-drug conjugated nanoparticles in metastatic breast cancer: mechanism, clinical advances, and translational opportunities","volume":"10","author":"Nayak","year":"2026","journal-title":"Next Nanotechnol"},{"key":"2026100105270858600_ref49","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.ntm.2023.100018","article-title":"The challenges to develop antibody-conjugated nanomedicine products","volume":"2","author":"Hui","year":"2023","journal-title":"Nano Trans Med"},{"key":"2026100105270858600_ref50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.addr.2019.05.010","article-title":"Ligand density on nanoparticles: a parameter with critical impact on nanomedicine","volume":"143","author":"Alkilany","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"2026100105270858600_ref51","doi-asserted-by":"publisher","first-page":"e1988","DOI":"10.1002\/wnan.1988","article-title":"Polymer\u2013drug and polymer\u2013protein conjugated nanocarriers: design, drug delivery, imaging, therapy, and clinical applications","volume":"16","author":"Guo","year":"2024","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"2026100105270858600_ref52","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","article-title":"Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs","volume":"8","author":"Dilliard","year":"2023","journal-title":"Nat Rev Mater"},{"key":"2026100105270858600_ref53","doi-asserted-by":"publisher","first-page":"e2109210","DOI":"10.1002\/adma.202109210","article-title":"Antibody-incorporated nanomedicines for cancer therapy","volume":"34","author":"Wu","year":"2022","journal-title":"Adv Mater"},{"key":"2026100105270858600_ref54","doi-asserted-by":"publisher","first-page":"2312169","DOI":"10.1002\/adma.202312169","article-title":"Nanomedicine tumor targeting","volume":"36","author":"Lammers","year":"2024","journal-title":"Adv Mater"},{"key":"2026100105270858600_ref55","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41420-024-01845-3","article-title":"Antibody and antibody fragments site-specific conjugation using new Q-tag substrate of bacterial transglutaminase","volume":"10","author":"El Alaoui","year":"2024","journal-title":"Cell Death Discov"},{"key":"2026100105270858600_ref56","doi-asserted-by":"publisher","first-page":"118274","DOI":"10.1016\/j.biopha.2025.118274","article-title":"Targeting prostate cancer with site-specific antibody-drug conjugates enabled by tandemly fused ADP-ribosyl cyclases","volume":"189","author":"Zhang","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"2026100105270858600_ref57","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41467-025-67661-0","article-title":"A versatile platform for chemical engineering of exosomes empowered by ADP-ribosyl cyclases","volume":"17","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"key":"2026100105270858600_ref58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.taap.2016.01.005","article-title":"Understanding the immunogenicity and antigenicity of nanomaterials: past, present and future","volume":"299","author":"Ilinskaya","year":"2016","journal-title":"Toxicol Appl Pharmacol"},{"key":"2026100105270858600_ref59","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/cells13090781","article-title":"Nuclear mTOR signaling orchestrates transcriptional programs underlying cellular growth and metabolism","volume":"13","author":"Zhao","year":"2024","journal-title":"Cells"},{"key":"2026100105270858600_ref60","doi-asserted-by":"publisher","first-page":"113991","DOI":"10.1016\/j.jconrel.2025.113991","article-title":"Clinical cancer nanomedicines","volume":"385","author":"Pallares","year":"2025","journal-title":"J Control Release"},{"key":"2026100105270858600_ref61","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1021\/acs.biomac.2c01090","article-title":"A poly-ADP-ribose polymer\u2013GCSF conjugate","volume":"23","author":"Cheng","year":"2022","journal-title":"Biomacromolecules"},{"key":"2026100105270858600_ref62","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1021\/acs.biochem.2c00718","article-title":"Synthesis of bispecific antibody conjugates using functionalized poly-ADP-ribose polymers","volume":"62","author":"Cheng","year":"2023","journal-title":"Biochemistry"},{"key":"2026100105270858600_ref63","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody\u2013oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2026100105270858600_ref64","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1039\/D2CS00141A","article-title":"Degrader-antibody conjugates","volume":"51","author":"Dragovich","year":"2022","journal-title":"Chem Soc Rev"},{"key":"2026100105270858600_ref65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2025.0512","article-title":"Enhancing cancer immunotherapy through polymer-based antibody conjugation technologies","volume":"23","author":"Chu","year":"2025","journal-title":"Cancer Biol Med"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbag042\/70684514\/tbag042.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/4\/566\/70684514\/tbag042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/4\/566\/70684514\/tbag042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:27:24Z","timestamp":1790846844000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/9\/4\/566\/8763747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbag042","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,18]]}}}